Published in ScientificWorldJournal on August 01, 2012
VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol (2014) 0.92
Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD. Graefes Arch Clin Exp Ophthalmol (2014) 0.79
Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia. Exp Ther Med (2015) 0.78
Expression analysis of an evolutionarily conserved alternative splicing factor, Sfrs10, in age-related macular degeneration. PLoS One (2013) 0.78
Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population. Int J Clin Exp Med (2015) 0.75
Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. Br J Ophthalmol (2016) 0.75
Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol (2004) 18.86
An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol (1995) 10.05
Detection and integration of genotyping errors in statistical genetics. Am J Hum Genet (2002) 4.89
Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol (2006) 2.82
Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum Hered (2002) 2.74
Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73
A transmission/disequilibrium test that allows for genotyping errors in the analysis of single-nucleotide polymorphism data. Am J Hum Genet (2001) 2.68
The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol (2003) 2.63
Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol (2009) 2.31
Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA (2006) 2.15
CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered (2006) 1.62
Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci (2006) 1.60
VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet (2006) 1.57
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res (2008) 1.38
Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol (2007) 1.35
The Bowman lecture. Towards an understanding of age-related macular disease. Eye (Lond) (2003) 1.31
Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pac Symp Biocomput (2003) 1.23
C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol (2007) 1.15
Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol (2008) 1.12
Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol Vis (2009) 1.00
Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology (2008) 0.99
Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch (2010) 0.98
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics (2007) 0.98
A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis (2007) 0.98
VEGF gene haplotypes are associated with sarcoidosis. Chest (2009) 0.89
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics (2012) 0.85
G/R 241 polymorphism of intercellular adhesion molecule 1 (ICAM-1) is associated with Fuchs uveitis. Invest Ophthalmol Vis Sci (2010) 0.83
Estrogen receptor alpha gene polymorphisms associated with incident aging macula disorder. Invest Ophthalmol Vis Sci (2007) 0.81
Genetic testing for age-related macular degeneration. Ophthalmology (2006) 0.77
Selenium and the course of mild Graves' orbitopathy. N Engl J Med (2011) 3.06
Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol (2002) 2.77
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol (2008) 2.70
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65
Molecular basis of resistance to azole antifungals. Trends Mol Med (2002) 2.48
Blindness following cosmetic injections of the face. Plast Reconstr Surg (2012) 2.41
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res (2006) 2.38
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res (2010) 2.22
Long-term perimetric fluctuation in patients with different stages of glaucoma. Br J Ophthalmol (2010) 2.02
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets (2012) 1.99
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res (2004) 1.79
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
In vivo analysis of conjunctiva in gold micro shunt implantation for glaucoma. Br J Ophthalmol (2010) 1.66
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer (2011) 1.59
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat (2003) 1.54
Enhancement of the core near-band-edge emission induced by an amorphous shell in coaxial one-dimensional nanostructure: the case of SiC/SiO2 core/shell self-organized nanowires. Nanotechnology (2010) 1.50
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol (2004) 1.48
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2008) 1.46
Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol (2006) 1.45
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther (2002) 1.39
Aceclidine, brimonidine tartrate, and dapiprazole: comparison of miotic effect and tolerability under different lighting conditions. J Cataract Refract Surg (2009) 1.39
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev (2012) 1.39
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol (2008) 1.37
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol (2005) 1.31
Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol (2003) 1.29
Periorbital necrotising fasciitis. Br J Ophthalmol (2009) 1.28
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol (2002) 1.27
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica (2011) 1.25
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Iatrogenic retinal artery occlusion caused by cosmetic facial filler injections. Am J Ophthalmol (2013) 1.20
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther (2006) 1.20
Polycomb genes and cancer: time for clinical application? Crit Rev Oncol Hematol (2011) 1.19
Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol (2012) 1.18
Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet (2010) 1.16
Histological findings of failed gold micro shunts in primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol (2011) 1.15
Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness. Cont Lens Anterior Eye (2010) 1.15
Promoting predictive, preventive and personalised medicine: European event of global importance. EPMA J (2011) 1.14
Supraciliary shunt in refractory glaucoma. Br J Ophthalmol (2011) 1.13
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther (2008) 1.13
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol (2007) 1.12
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res (2004) 1.11
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol (2004) 1.10
CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci (2007) 1.09
Biomarkers and response to bevacizumab--letter. Clin Cancer Res (2014) 1.09
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer (2011) 1.08
Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab (2007) 1.08
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol (2004) 1.08
Breast lymphomas around breast implants. Ann Surg (2014) 1.07
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.06
The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis (2013) 1.05
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol (2011) 1.04
Macular pucker: to peel or not to peel the internal limiting membrane? A microperimetric response. Retina (2015) 1.03
Incorporating corneal pachymetry into the management of glaucoma. J Cataract Refract Surg (2009) 1.03
Cancer stem cell epigenetics and chemoresistance. Epigenomics (2009) 1.03
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets (2005) 1.02
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics (2013) 1.02
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol (2009) 1.01
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab (2011) 1.01
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit (2010) 1.01
Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab (2011) 1.00
Biological parameters determining the clinical outcome of autologous cultures of limbal stem cells. Regen Med (2013) 1.00
Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin Investig Drugs (2002) 0.99
Semantic relevance explains category effects in medial fusiform gyri. Neuroimage (2005) 0.99
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther (2007) 0.98
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat (2011) 0.98
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther (2012) 0.98
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics (2007) 0.98
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis (2012) 0.96
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res (2008) 0.96